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Currently, much effort is invested in the 
development and optimization of in vitro 
systems for toxicity testing (Godoy et al., 
2013; Sisnaiske et al., 2014; Grinberg et al., 
2014; Stewart and Marchan, 2012; Hengstler 
et al., 2012). However, one major problem in 
this field of research is the difficulty to link 
observations made in vitro to adverse effects 
in vivo (Ghallab, 2013; Bolt, 2013). To come 
closer to a solution of this fundamental prob-
lem, Waldmann et al. (2014) performed a 
study in which they systematically analysed 
concentration-dependent transcriptome alter-
ations of valproic acid in relation to human 
blood concentrations known to cause terato-
genic effects. Waldmann and colleagues 
used human stem cells that differentiate to 
neuronal precursor cells during a 6-days pe-
riod, a test system recently developed for 
developmental neurotoxicity testing (Krug et 
al., 2013; Weng et al., 2014; Balmer et al., 
2014; Zimmer et al., 2014; Leist et al., 
2013). Based on the results of genome-wide 
expression alterations the authors identified 
three concentration ranges: (1) A range of 
tolerance below 25 µM valproic acid, where 
no gene expression deregulation was ob-
served; (2) a range of deregulation between 
15 and 550 µM valproic acid. In this concen-
tration range numerous genes involved in 
regulation of neuronal development were 
deregulated. Interestingly, this represents the 
range of VPA concentrations in blood, where 
developmental toxicity has been observed in 
humans. (3) The concentration range above 
800 µM valproic acid, where cytotoxic ef-
fects were observed. However, such high 
concentrations are usually not obtained in 
patients. 
Currently, developmental toxicity testing 
in vitro represents a cutting-edge topic, be-
cause animal tests are extremely cost- and 
labor- intensive (Strikwold et al., 2013; Stern 
et al., 2014; Driessen et al., 2013; Cordova et 
al., 2013; Hoelting et al., 2013; Tonk et al., 
2013; van Thriel and Stewart, 2012; Marius-
sen, 2012; Frimat et al., 2010). However, 
only few studies systematically compared 
how concentration ranges that induce (or do 
not induce) adverse effects in vivo influence 
biomarkers in in vitro systems. The study of 
Waldmann et al. (2014) sets an example how 
this type of study can be designed. Of 
course, future work is required to see wheth-
er the good in vitro/in vivo correlation ob-
served for valproic acid will be confirmed 
for further chemicals known to induce de-
velopmental toxicity. 
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